Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes

Journal of Human Hypertension

Volumn 28, Issue 1, 2014, Pages 37-43

  Noshad, S ^a   Mousavizadeh, M ^a   Mozafari, M ^a   Nakhjavani, M ^a   Esteghamati, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood pressure visit to visit variability; Diabetic nephropathy; Microalbuminuria; Type 2 diabetes

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C; CREATININE; GLUCOSE BLOOD LEVEL; INSULIN; LIPID;

ADULT; ARTICLE; BLOOD PRESSURE VARIABILITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; AGED; ALBUMINURIA; ANALYSIS; BLOOD; BLOOD PRESSURE MEASUREMENT; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRAN; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE DETERMINATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN; IRAN; LIPIDS; MALE; MIDDLE AGED; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84889664790     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.36     Document Type: Article

References (46)

1. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-S63.
2. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
3. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999; 159: 1873-1880.
4. Lambers Heerspink HJ, de Zeeuw D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 458-461, discussion 468.
5. Afghahi H, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S, Hadimeri H et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes-the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant 2011; 26: 1236-1243.
6. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063.
7. Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care 2010; 33: 2442-2447.
8. Okada H, Fukui M, Tanaka M, Inada S, Mineoka Y, Nakanishi N et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis 2012; 220: 155-159.
9. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54: 2983-2987.
10. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B et al. Effects of b blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurology 2010; 9: 469-480.
11. Parati G, Bilo G. Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring. Hypertension 2012; 59: 1091-1093.
12. Parati G, Ochoa JE, Bilo G. Blood pressure variability, cardiovascular risk, and risk for renal disease progression. Curr Hypertens Rep 2012; 14: 421-431.
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
14. Jackson S. Creatinine in urine as an index of urinary excretion Rate. Health Physics 1966; 12: 843-850.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl 1): S64-S71.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
17. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
18. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
19. Mena L, Pintos S, Queipo NV, Aizpurua JA, Maestre G, Sulbaran T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens 2005; 23: 505-511.
20. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5: 93.
21. Ekbom T, Dahlof B, Hansson L, Lindholm LH, Oden A, Schersten B et al. The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure-insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Blood Press 1992; 1: 168-172.
22. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11: 1133.
23. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C et al. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens 1998; 16: 733-738.
24. Parati G, Ravogli A, Frattola A, Groppelli A, Ulian L, Santucciu C et al. Blood pressure variability: clinical implications and effects of antihypertensive treatment. J Hypertens Suppl 1994; 12: S35-S40.
25. Tozawa M, Iseki K, Yoshi S, Fukiyama K. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 1976-1981.
26. Carlberg B, Lindholm LH. Stroke and blood-pressure variation: new permutations on an old theme. Lancet 2010; 375: 867-869.
27. Hsieh YT, Tu ST, Cho TJ, Chang SJ, Chen JF, Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5.5-year prospective analysis. Eur J Clin Invest 2012; 42: 245-253.
28. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population. Hypertension 2011; 57: 160-166.
29. Palmas W, Pickering TG, Teresi J, Schwartz JE, Moran A, Weinstock RS et al. Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus. Hypertension 2009; 53: 120-127.
30. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
31. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Int Med 2003; 163: 1555.
32. Kawai T, Ohishi M, Kamide K, Onishi M, Takeya Y, Tatara Y et al. The impact of visitto-visit variability in blood pressure on renal function. Hypertens Res 2011; 35: 239-243.
33. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18: 572-581.
34. Mogensen CE. Microalbuminuria, early blood pressure elevation, and diabetic renal disease. Curr Opin Endocrin, Diab Obes 1994; 1: 239-248.
35. Gomes MB, Goncalves MF. Is there a physiological variability for albumin excretion rate? Study in patients with diabetes type 1 and non-diabetic individuals. Clin Chim Acta 2001; 304: 117-123.
36. Chau NP, Bouhanick B, Mestivier D, Taki M, Marre M. Normal and abnormal dayto-day variability of urinary albumin excretion in control and diabetic subjects. Diabetes Metab 2000; 26: 36-41.
37. Perkins RM, Tang X, Bengier AC, Kirchner HL, Bucaloiu ID. Variability in estimated glomerular filtration rate is an independent risk factor for death among patients with stage 3 chronic kidney disease. Kidney Int 2012; 82: 1332-1338.
38. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23: 1052-1060.
39. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
40. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57: 846-851.
41. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertnes 2002; 20: 2183.
42. Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S et al. Reduced endothelial vasomotor function and enhanced neointimal formation after vascular injury in a rat model of blood pressure lability. Hypertens Res 2003; 26: 991-998.
43. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82-90.
44. Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY. Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. Hypertension 2011; 57: 490-496.
45. Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) 2012; 14: 744-750.
46. Howard SC, Rothwell PM. Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. Cerebrovasc Dis 2009; 28: 331-340.